Geoff Hale

Geoff Hale

Auto-generated profile, based on publicly available information

Geoff Hale

Absolve Limited

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IWIan Wilkinson
Ian Wilkinson
SAStephen Anderson
Stephen Anderson
JFJeremy Fry
Jeremy Fry
LJLouis Alex Julien
Louis Alex Julien
DNDavid Neville
David Neville
GHGeoff Hale
Geoff Hale
Elimination of the binding of immunoglobulin Fc to Fc gamma receptors (FcγR) is highly desirable for the avoidance of unwanted inflammatory responses to therapeutic antibodies and fusion proteins. Many different approaches have been described in the literature but none of them completely eliminates binding to all of the Fcγ receptors. Here we describe a set of novel variants having specific amino acid substitutions in the Fc region at L234 and L235 combined with the substitution G236R. They show no detectable binding to Fcγ receptors or to C1q, are inactive in functional cell-based assays and do not elicit inflammatory cytokine responses. Meanwhile, binding to FcRn, manufacturability, stability and potential for immunogenicity are unaffected. These variants have the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.

19 August 2024 in Immunological Reviews
Verified
Journal Article
Open access
GHGeoff Hale
Geoff Hale
Summary: The Fc region of antibodies is vital for most of their physiological functions, many of which are engaged through binding to a range of Fc receptors. However, these same interactions are not always helpful or wanted when therapeutic antibodies are directed against self‐antigens, and can sometimes cause catastrophic adverse reactions. Over the past 40 years, there have been intensive efforts to “silence” unwanted binding to Fc‐gamma receptors, resulting in at least 45 different variants which have entered clinical trials. One of the best known is “LALA” (L234A/L235A). However, neither this, nor most of the other variants in clinical use are completely silenced, and in addition, the biophysical properties of many of them are compromised. I review the development of different variants to see what we can learn from their biological properties and use in the clinic. With the rise of powerful new uses of antibody therapy such as bispecific T‐cell engagers, antibody‐drug conjugates, and checkpoint inhibitors, it is increasingly important to optimize the Fc region as well as the antibody binding site in order to achieve the best combination of safety and efficacy.

15 September 2022 in mAbs
Verified
Journal Article
Open access
IWIan Wilkinson
Ian Wilkinson
GHGeoff Hale
Geoff Hale
By combining and cross-checking data from the World Health Organization’s lists of international nonproprietary names with three other databases, we assembled a dataset of amino acid sequences of 819 antibody-related therapeutics. This enabled the systematic tabulation of 57 different molecular formats and about 90 different constant-region variants (47 for silencing, 14 for enhancement, 8 for modifying binding to FcRn, 13 for heterodimerization, 4 for site-specific modification and 4 for stabilization), as well as the frequencies of different targets and immunoglobulin allotypes. The curated dataset provides a resource for researchers, giving insights into trends in antibody engineering and a guide to the most frequently tested designs.

15 September 2024 in mAbs
Verified
Journal Article
Open access
GHGeoff Hale
Geoff Hale
JVJelle De Vos
Jelle De Vos
ADAlastair Douglas Davy
Alastair Douglas Davy
KSKoen Sandra
Koen Sandra
IWIan Wilkinson
Ian Wilkinson
Elimination of the binding of immunoglobulin Fc to Fc gamma receptors is highly desirable for the avoidance of unwanted inflammatory responses to therapeutic antibodies and fusion proteins. Many different approaches have been used in the clinic, but they have not been systematically compared. We have now produced a matched set of anti-CD20 antibodies with different Fc subclasses and variants and compared their activity for binding to C1q, Fc-gamma receptors and in cell-based assays. Most of the variants still have significant levels of activity in one or more of these assays and many of them have impaired temperature stability compared with the corresponding wild-type antibody.

22 September 2024 in mAbs
Verified
Journal Article
Open access
GHGeoff Hale
Geoff Hale
ADAlastair Douglas Davy
Alastair Douglas Davy
IWIan Wilkinson
Ian Wilkinson
A critical attribute of therapeutic antibodies is their ability to engage with humoral or cellular effector mechanisms, and this depends on the ability of the Fc region to bind to complement (C1q) or Fc receptors. Investigators have sought to optimize these effects by engineering the Fc region to bind to a greater or lesser extent to individual receptors. Different approaches have been used in the clinic, but they have not been systematically compared. We have now produced a matched set of anti-CD20 antibodies representing a range of variants and compared their activity in cell-based assays for complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent phagocytosis using a range of individual Fc receptors. We have also compared the thermal stability of the variants by differential scanning fluorimetry (DSF). The results reveal a spectrum of activities which may be appropriate for different applications.

1 January 2002 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
GHGeoff Hale
Geoff Hale